Section Arrow
Quote
ACAD.NASDAQ
- ACADIA Pharmaceuticals
Quotes are at least 15-min delayed:2026/05/08 03:33 EDT
Regular Hours
Last
 22.56
+1.08 (+5.03%)
Day High 
22.84 
Prev. Close
21.48 
1-M High
23.07 
Volume 
3.67M 
Bid
--
Ask
--
Day Low
21.52 
Open
21.89 
1-M Low
20.96 
Market Cap 
3.68B 
Currency 美元 
P/E 9.34 
%Yield -- 
10-SMA 22.17 
20-SMA 22.04 
50-SMA 22.04 
52-W High 28.35 
52-W Low 16.86 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.30/0.86
Enterprise Value
3.72B
Balance Sheet
Book Value Per Share
7.17
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
1.07B
Operating Revenue Per Share
3.69
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.155-0.031-16.67%-- 
ATRAAtara Biotherapeutics Inc.9.93+4.78+92.82%2PE
IOVAIovance Biotherapeutics3.55-0.54-13.20%-- 
ADMAADMA Biologics8.47-1.61-15.97%16.8PE
ENGNenGene Therapeutics Inc1.72-7.13-80.56%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.